Clinical Roundup Opdivo + Cabometyx shows durable survival in three-year follow-up for first-line advanced RCC February 17, 2023Vol.49 No.07
Clinical Roundup Interim phase II results show positive safety and efficacy data for bel-sar in early-stage choroidal melanoma February 17, 2023Vol.49 No.07
Clinical Roundup Moffitt researchers discover pathways to activate dendritic cells, produce strong anti-tumor immunity February 17, 2023Vol.49 No.07
Clinical Roundup NY Proton Center initiates three studies on FLASH radiation therapy February 17, 2023Vol.49 No.07
Clinical Roundup Lung cancer study finds new target for treatment resistance after EGFR inhibitors February 17, 2023Vol.49 No.07
Clinical Roundup Research reveals why cancers stop responding to kinase-blocking drugs February 17, 2023Vol.49 No.07
Drugs & Targets Gritstone bio and NCI collaborate to evaluate neoantigen cell therapy + vaccine for mutant KRAS solid tumors February 17, 2023Vol.49 No.07
Drugs & Targets MD Anderson and Xilis collaborate on preclinical research February 17, 2023Vol.49 No.07
NCI Bertagnolli raises paylines, creates Clinical Trials Innovation Unit, and announces National Cancer Plan February 10, 2023Vol.49 No.06By Matthew Bin Han Ong
Guest Editorial A Super Bowl LVII challenge: It’s Chiefs/KU vs. Eagles/SKCC February 10, 2023Vol.49 No.06By Matthew Huesser and Christine Thomas
